The use of synthetic estrogen for women experiencing menopause—particularly those who have previously been treated for breast cancer—has long sparked debate among medical professionals.
In an effort to clarify misconceptions and provide evidence-based guidance, gynecologic oncologist Dr. Nicole Gaulin and Dr. Sheheryar Kabraji, Chief of Breast Medicine at Roswell Park Comprehensive Cancer Center, address key questions about hormone replacement therapy (HRT).
Understanding Hormone Replacement Therapy
Hormone replacement therapy involves supplementing estrogen and/or progesterone, hormones naturally produced by the ovaries, to compensate for reduced levels during menopause. According to Dr. Gaulin, HRT is not limited to natural menopause. It may also be prescribed for women who experience surgical menopause due to cancer treatment, ovarian cancer, or ovarian damage from chemotherapy or radiation.
“Ovarian insufficiency is a debilitating condition,” Dr. Gaulin explains. “Women affected face increased risks of cardiac events, fractures, osteoporosis, and genitourinary symptoms such as vaginal dryness, painful intercourse, and recurrent urinary tract infections.”
Addressing Concerns About HRT Safety
HRT’s safety has been questioned since the 1990s when the Women’s Health Initiative highlighted potential adverse outcomes. However, these early studies excluded women with primary ovarian insufficiency and younger women experiencing early menopause.
“Current data strongly support HRT use in these women,” Dr. Gaulin notes. “Hormone therapy significantly reduces the risk of vertebral and hip fractures, and it also lowers the nearly 50% elevated risk of ischemic cardiac events seen in early menopause.”
Options for Symptom Management
Treatment options include oral contraceptives, lower-dose hormone patches, and oral medications. Intravaginal estrogen is considered a highly effective and safe option for treating vaginal symptoms, including dryness, pain, and recurrent infections.
For breast cancer patients, Dr. Kabraji emphasizes that reducing estrogen can be part of cancer treatment. “This approach may lead to side effects such as hot flashes, joint pain, and genitourinary issues,” he says. “While data on HRT use after breast cancer are mixed, the overall risk of recurrence is generally low. Topical estrogen may offer significant benefits for symptom management in these cases, and discussions between patients and doctors are encouraged.”
HRT After Natural Menopause
Dr. Kabraji notes that much of the older data guiding HRT recommendations involve higher doses of estrogen than are typically prescribed today. The use of HRT after natural menopause is nuanced and generally recommended for women under 60, offering favorable outcomes compared to older patients.
“Every woman should discuss her individual risk-benefit profile with a physician before starting HRT,” Dr. Gaulin advises. “This ensures treatment decisions are based on medical evidence and personal health needs.”
YOU MAY ALSO LIKE
Standing More Often Reduce Blood Pressure in Postmenopausal Women
Persistent Menopause Symptoms Linked to Little-Known Syndrome
Scientists Capture First IVF Embryo Implantation in Real Time
